Efecto del litio sobre el suicidio en los trastornos del humor

1 Kessler RC, Angermeyer M, Anthony JC, DE Graaf R, Demyttenaere K, Gasquet I, et al. Lifetime prevalence and age-of-onset distributions of mental disorders in the World Health Organization’s World Mental Health Survey Initiative. World Psychiatry 2007;6:168-76.
2 Gore FM, Bloem PJ, Patton GC, Ferguson J, Joseph V, Coffey C, et al. Global burden of disease in young people aged 10-24 years: a systematic analysis. Lancet 2011;377:2093-102.
3 Mathers CD, Loncar D. Projections of global mortality and burden of disease from 2002 to 2030. PLoS Med 2006;3:e442.
4 Kupfer DJ, Frank E, Phillips ML. Major depressive disorder: new clinical, neurobiological, and treatment perspectives. Lancet 2012;379:1045-55.
5 Harris EC, Barraclough B. Suicide as an outcome for mental disorders. A meta-analysis. Br J Psychiatry 1997;170:205-28.
6 Nordentoft M, Mortensen PB, Pedersen CB. Absolute risk of suicide after first hospital contact in mental disorder. Arch Gen Psychiatry 2011;68:1058-64.
7 Department of Health. National suicide prevention strategy for England. Department of Health, 2002.
8 US Department of Health Human Services. National strategy for suicide prevention: goals and objectives for action. US Department of Health and Human Services, Public Health Service, 2001.
9 Saunders KE, Hawton K. The role of psychopharmacology in suicide prevention. Epidemiol Psichiatr Soc 2009;18:172-8.
10 Cipriani A, Pretty H, Hawton K, Geddes JR. Lithium in the prevention of suicidal behavior and all-cause mortality in patients with mood disorders: a systematic review of randomized trials. Am J Psychiatry 2005;162:1805-19.
11 Perlis RH. Hard outcomes: clinical trials to reduce suicide. Am J Psychiatry 2011;168:1009-11.
12 Higgins JPT, Altman DG, Sterne JAC, eds. Chapter 8: assessing risk of bias in included studies. In: Higgins JPT, Green S, eds. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
13 National Institute for Health and Clinical Excellence. Self-harm: longer-term management. (Clinical guideline 133.) 2011. www.nice.org.uk/CG133.
14 Hawton K, Harriss L, Hall S, Simkin S, Bale E, Bond A. Deliberate self-harm in Oxford, 1990-2000: a time of change in patient characteristics. Psychol Med 2003;33:987-95.
15 Skegg K. Self-harm. Lancet 2005;366:1471-83. 16 Madge N, Hewitt A, Hawton K, de Wilde EJ, Corcoran P, Fekete S, et al. Deliberate self-harm within an international community sample of young people: comparative findings from the child & adolescent self-harm in Europe (CASE) study. J Child Psychol Psychiatry 2008;49:667-77.
17 Owens D, Horrocks J, House A. Fatal and non-fatal repetition of self-harm. Systematic review. Br J Psychiatry 2002;181:193-9.
18 McKnight RF, Adida M, Budge K, Stockton S, Goodwin GM, Geddes JR. Lithium toxicity profile: a systematic review and meta-analysis. Lancet 2012;379:721-8.
19 Sweeting MJ, Sutton AJ, Lambert PC. What to add to nothing? Use and avoidance of continuity corrections in meta-analysis of sparse data. Stat Med 2004;23:1351-75.
20 Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003;327:557-60.
21 Baldessarini RJ, Tondo L, Davis P, Pompili M, Goodwin FK, Hennen J. Decreased risk of suicides and attempts during long-term lithium treatment: a meta-analytic review. Bipolar Disord 2006;8:625-39.
22 Gonzalez-Pinto A, Mosquera F, Alonso M, López P, Ramírez F, Vieta E, et al. Suicidal risk in bipolar I disorder patients and adherence to long-term lithium treatment. Bipolar Disord 2006;8:618-24.
23 Guzzetta F, Tondo L, Centorrino F, Baldessarini RJ. Lithium treatment reduces suicide risk in recurrent major depressive disorder. J Clin Psychiatry 2007;68:380-3.
24 Yerevanian BI, Koek RJ, Mintz J. Bipolar pharmacotherapy and suicidal behavior. Part I: lithium, divalproex and carbamazepine. J Affect Disord 2007;103:5-11.
25 Simon GE, Savarino J, Operskalski B, Wang PS. Suicide risk during antidepressant treatment. Am J Psychiatry 2006;163:41-7.
26 Egger M, Smith GD. Bias in location and selection of studies. BMJ 1998;316:61-6.
27 Geddes JR, Burgess S, Hawton K, Jamison K, Goodwin GM. Long-term lithium therapy for bipolar disorder: systematic review and meta-analysis of randomized controlled trials.Am J Psychiatry 2004;161:217-22.
28 Geddes JR, Goodwin GM, Rendell J, Azorin JM, Cipriani A, Ostacher MJ, et al. Lithium plus valproate combination therapy versus monotherapy for relapse prevention in bipolar I disorder (BALANCE): a randomised open-label trial. Lancet 2010;375:385-95.
29 Cipriani A, Smith K, Burgess S, Carney S, Goodwin G, Geddes J. Lithium versus antidepressants in the long-term treatment of unipolar affective disorder. Cochrane Database Syst Rev 2006;(4):CD003492.
30 National Institute for Health and Clinical Excellence. Depression: the treatment and management of depression in adults (update) (Clinical guideline 90.) 2009. www.nice.org. uk/CG90.
31 Cipriani A, Barbui C, Butler R, Hatcher S, Geddes J. Depression in adults: drug and physical treatments. Clin Evid (Online) 2011;pii:1003.
32 Kovacsics CE, Gottesman II, Gould TD. Lithium’s antisuicidal efficacy: elucidation of neurobiological targets using endophenotype strategies. Ann Rev Pharmacol Toxicol 2009;49:175-98.
33 Ernst CL, Goldberg JF. Antisuicide properties of psychotropic drugs: a critical review. Harv Rev Psychiatry 2004;12:14-41.
34 Mann JJ, Waternaux C, Haas GL, Malone KM. Toward a clinical model of suicidal behavior in psychiatric patients. Am J Psychiatry 1999;156:181-9.
35 O’Donnell KC, Gould TD. The behavioral actions of lithium in rodent models: leads to develop novel therapeutics. Neurosci Biobehav Rev 2007;31:932-62.
36 Bondy B, Buettner A, Zill P. Genetics of suicide. Mol Psychiatry 2006;11:336-51.
37 Currier D, Mann JJ. Stress, genes and the biology of suicidal behavior. Psychiatr Clin North Am 2008;31:247-69.
38 Malhi GS, Tanious M. Optimal frequency of lithium administration in the treatment of bipolar disorder. Clinical and dosing considerations. CNS Drugs 2011;25:1-10.